S&P 500 7,420.10 â–ŧ 91.25 (-1.21%) DOW 51,492.55 â–ŧ 507.12 (-0.98%) NASDAQ 26,021.66 â–ŧ 354.69 (-1.34%) US Markets Closed â€ĸ 09:16 AM ET

BIVIW

BioVie Inc.

Price Chart
Latest Quote

$0.31

+0.03 (+12.51%)
Current Price
Previous Close $0.28
Open $0.31
Day High $0.31
Day Low $0.31
Volume 1,500
Fetched: 2026-06-18T13:16:39
Stock Information
Total Debt $296K
Cash Equivalents $13.10M
Net Income $-19.96M
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Income$-19.96M
Book/sh$2.07
Employees13
Financial Ratios
Quick Ratio9.02
Current Ratio9.97
Debt/Eq1.90
Returns & Margins
ROA-61.04%
ROE-106.43%
Ownership
Insider & Institutional transactions data not available
Valuation Ratios
P/B0.15
Analyst Data
Recommendationnone
Technical Indicators
SMA20$nan
SMA50$nan
RSInan
ATRnan
Shares Float7.50M
Volatility0.65
Rel Volume20.00
Performance History
Weeknan%
Monthnan%
Quarternan%
YTDnan%
10 Yearsnan%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-17 $nan 1,500
2026-06-12 $0.35 0
2026-06-11 $0.35 0
2026-06-10 $0.35 0
2026-06-09 $0.35 0
2026-06-08 $0.35 0
2026-06-05 $0.35 0
2026-06-04 $0.35 0
2026-06-03 $0.35 0
2026-06-02 $0.35 0
2026-06-01 $0.35 0
2026-05-29 $0.35 0
2026-05-28 $0.35 0
2026-05-27 $0.35 0
2026-05-26 $0.35 0
2026-05-22 $0.35 0
2026-05-21 $0.35 0
2026-05-20 $0.35 0
2026-05-19 $0.35 0
2026-05-18 $0.35 0
About BioVie Inc.

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Period:
Loading...
Income Statement (Annual)
Metric 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Interest Expense $332,720 $2,893,922 $4,300,150 $2,162,989
Total Expenses $18,066,200 $32,179,585 $45,080,448 $27,252,977
Other Income Expense $3,771 $1,816,271 $-1,437,481 $3,287,418
Net Non Operating Interest Income Expense $520,309 $-1,757,219 $-3,737,886 $-2,118,909
Interest Expense Non Operating $332,720 $2,893,922 $4,300,150 $2,162,989
Operating Expense $18,066,200 $32,179,585 $45,080,448 $27,252,977
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-17,542,120 $-32,120,533 $-50,255,815 $-26,084,468
Net Interest Income $520,309 $-1,757,219 $-3,737,886 $-2,118,909
Interest Income $853,029 $1,136,703 $562,264 $44,080
Normalized Income $-17,545,891 $-33,936,804 $-48,818,334 $-29,371,886
Net Income From Continuing And Discontinued Operation $-17,542,120 $-32,120,533 $-50,255,815 $-26,084,468
Total Operating Income As Reported $-18,066,200 $-32,179,585 $-45,080,448 $-27,252,977
Net Income Common Stockholders $-17,911,585 $-33,006,956 $-50,255,815 $-26,084,468
Net Income $-17,542,120 $-32,120,533 $-50,255,815 $-26,084,468
Net Income Including Noncontrolling Interests $-17,542,120 $-32,120,533 $-50,255,815 $-26,084,468
Net Income Continuous Operations $-17,542,120 $-32,120,533 $-50,255,815 $-26,084,468
Pretax Income $-17,542,120 $-32,120,533 $-50,255,815 $-26,084,468
Interest Income Non Operating $853,029 $1,136,703 $562,264 $44,080
Operating Income $-18,066,200 $-32,179,585 $-45,080,448 $-27,252,977
Depreciation Amortization Depletion Income Statement $229,377 $229,377 $229,377 $229,377
Depreciation And Amortization In Income Statement $229,377 $229,377 $229,377 $229,377
Amortization Of Intangibles Income Statement $229,377 $229,377 $229,377 $229,377
Special Income Charges - - - $0
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-16,983,794 $-30,813,505 $-44,288,807 $-26,979,520
Total Unusual Items $3,771 $1,816,271 $-1,437,481 $3,287,418
Total Unusual Items Excluding Goodwill $3,771 $1,816,271 $-1,437,481 $3,287,418
Reconciled Depreciation $229,377 $229,377 $229,377 $229,377
EBITDA (Bullshit earnings) $-16,980,023 $-28,997,234 $-45,726,288 $-23,692,102
EBIT $-17,209,400 $-29,226,611 $-45,955,665 $-23,921,479
Diluted NI Availto Com Stockholders $-17,911,585 $-33,006,956 $-50,255,815 $-26,084,468
Otherunder Preferred Stock Dividend $369,465 $886,423 $0 $0
Gain On Sale Of Security $3,771 $1,816,271 $-1,437,481 $3,287,418
Amortization $229,377 $229,377 $229,377 $229,377
Research And Development $9,266,734 $23,100,394 $33,299,503 $17,258,341
Selling General And Administration $8,570,089 $8,849,814 $11,551,568 $9,765,259
Other Special Charges - - - -
Fetched: 2026-06-17
Balance Sheet (Annual)
Metric 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Assets
Net Tangible Assets $18,487,933 $14,752,786 $14,357,480 $2,458,752
Total Assets $21,562,199 $25,208,345 $35,104,730 $20,114,594
Total Non Current Assets $863,705 $1,160,155 $1,063,595 $1,334,999
Goodwill And Other Intangible Assets $524,052 $753,429 $982,806 $1,212,183
Other Intangible Assets $178,341 $407,718 $637,095 $866,472
Current Assets $20,698,494 $24,048,190 $34,041,135 $18,779,595
Other Current Assets $1,049,897 $204,392 $102,526 $137,879
Receivables $2,104,050 $0 - -
Other Receivables $2,104,050 - - -
Cash Cash Equivalents And Short Term Investments $17,544,547 $23,843,798 $33,938,609 $18,641,716
Cash And Cash Equivalents $17,544,547 $23,843,798 $19,460,883 $18,641,716
Cash Equivalents $13,566,276 $11,079,857 $13,156,340 -
Cash Financial $3,978,271 $12,763,941 $6,304,543 $18,641,716
Other Non Current Assets - - - $4,562
Prepaid Assets - - - $137,879
Debt
Total Debt $349,894 $6,111,447 $14,419,758 $12,264,984
Long Term Debt And Capital Lease Obligation $275,430 $349,894 $5,269,775 $12,226,100
Current Debt And Capital Lease Obligation $74,464 $5,761,553 $9,149,983 $38,884
Current Debt - $5,701,210 $9,105,074 -
Other Current Borrowings - $5,701,210 $9,105,074 -
Long Term Debt - - $5,227,270 $12,138,686
Liabilities
Total Liabilities Net Minority Interest $2,550,214 $9,702,130 $19,764,444 $16,443,659
Total Non Current Liabilities Net Minority Interest $275,430 $349,894 $5,269,775 $12,274,485
Current Liabilities $2,274,784 $9,352,236 $14,494,669 $4,169,174
Payables And Accrued Expenses $2,200,320 $3,586,912 $3,476,259 $2,442,804
Other Current Liabilities - $3,771 $1,868,427 $1,687,486
Other Non Current Liabilities - - - $48,385
Equity
Common Stock Equity $19,011,985 $15,506,215 $15,340,286 $3,670,935
Total Equity Gross Minority Interest $19,011,985 $15,506,215 $15,340,286 $3,670,935
Stockholders Equity $19,011,985 $15,506,215 $15,340,286 $3,670,935
Retained Earnings $-352,144,246 $-334,232,661 $-301,225,705 $-250,969,890
Gains Losses Not Affecting Retained Earnings - $0 $176,591 -
Other Equity Adjustments - - $176,591 -
Other
Treasury Shares Number $2,837 $2,632 $228 -
Ordinary Shares Number $1,914,224 $619,007 $364,289 $249,840
Share Issued $1,917,061 $621,639 $364,517 $249,840
Tangible Book Value $18,487,933 $14,752,786 $14,357,480 $2,458,752
Invested Capital $19,011,985 $21,207,425 $29,672,630 $15,809,621
Working Capital $18,423,710 $14,695,954 $19,546,466 $14,610,421
Capital Lease Obligations $349,894 $410,237 $87,414 $126,298
Total Capitalization $19,011,985 $15,506,215 $20,567,556 $15,809,621
Treasury Stock $29 $27 $2 $0
Additional Paid In Capital $371,148,784 $349,732,674 $316,385,759 $254,638,329
Capital Stock $7,476 $6,229 $3,643 $2,496
Common Stock $7,476 $6,229 $3,643 $2,496
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $275,430 $349,894 $42,505 $87,414
Current Capital Lease Obligation $74,464 $60,343 $44,909 $38,884
Goodwill $345,711 $345,711 $345,711 $345,711
Net PPE $339,653 $406,726 $80,789 $118,254
Gross PPE $339,653 $406,726 $80,789 $118,254
Buildings And Improvements $339,653 $406,726 $80,789 $118,254
Properties $0 $0 $0 $0
Other Short Term Investments - $0 $14,477,726 $0
Other Properties - - $80,789 $118,254
Fetched: 2026-06-17
Cash Flow Statement (Annual)
Metric 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Free Cash Flow
Free Cash Flow $-19,025,205 $-27,945,024 $-40,252,881 $-18,990,850
Operating Activities
Operating Cash Flow $-19,025,205 $-27,945,024 $-40,252,881 $-18,990,850
Cash Flow From Continuing Operating Activities $-19,025,205 $-27,945,024 $-40,252,881 $-18,990,850
Operating Gains Losses $-3,771 $-2,040,136 $1,437,481 $-3,287,418
Investing Activities
Investing Cash Flow $0 $14,525,000 $-14,301,135 $0
Cash Flow From Continuing Investing Activities $0 $14,525,000 $-14,301,135 $0
Financing Activities
Issuance Of Capital Stock $15,674,613 $27,802,939 $55,370,943 $18,511,009
Financing Cash Flow $12,725,954 $17,802,939 $55,373,183 $33,120,924
Cash Flow From Continuing Financing Activities $12,725,954 $17,802,939 $55,373,183 $33,120,924
Net Common Stock Issuance $15,674,613 $27,802,939 $55,370,943 $18,511,009
Common Stock Issuance $15,674,613 $27,802,939 $55,370,943 $18,511,009
Other
Repayment Of Debt $-5,850,000 $0 $0 $0
Interest Paid Supplemental Data $183,930 $1,525,056 $2,106,491 $964,241
End Cash Position $17,544,547 $23,843,798 $19,460,883 $18,641,716
Beginning Cash Position $23,843,798 $19,460,883 $18,641,716 $4,511,642
Changes In Cash $-6,299,251 $4,382,915 $819,167 $14,130,074
Proceeds From Stock Option Exercised $2,901,341 $-10,000,000 $2,240 $0
Net Issuance Payments Of Debt $-5,850,000 $0 $0 $14,609,915
Net Short Term Debt Issuance $-5,850,000 $0 - $14,609,915
Short Term Debt Payments $-5,850,000 $0 - -
Net Investment Purchase And Sale $0 $14,525,000 $-14,301,135 $0
Sale Of Investment $0 $14,525,000 - -
Change In Working Capital $-4,396,490 $-86,843 $-270,439 $2,750,786
Change In Other Current Liabilities $-60,343 $-95,630 $-1,343,809 $1,353,310
Change In Payables And Accrued Expense $-1,386,592 $110,653 $1,033,455 $1,446,430
Change In Prepaid Assets $-845,505 $-101,866 $39,915 $-48,954
Change In Receivables $-2,104,050 $0 - -
Other Non Cash Items $215,863 $1,412,997 $2,231,123 $1,206,794
Stock Based Compensation $2,471,936 $4,660,114 $6,375,392 $6,194,079
Depreciation Amortization Depletion $229,377 $229,377 $229,377 $229,377
Depreciation And Amortization $229,377 $229,377 $229,377 $229,377
Amortization Cash Flow $229,377 $229,377 $229,377 $229,377
Amortization Of Intangibles $229,377 $229,377 $229,377 $229,377
Gain Loss On Investment Securities $-3,771 $-2,040,136 $1,437,481 $-3,287,418
Net Income From Continuing Operations $-17,542,120 $-32,120,533 $-50,255,815 $-26,084,468
Net Long Term Debt Issuance - $-10,000,000 $0 $14,609,915
Long Term Debt Payments - $-10,000,000 $0 $0
Issuance Of Debt - - $0 $14,609,915
Long Term Debt Issuance - - $0 $14,609,915
Purchase Of Investment - - $-14,301,135 $0
Income Tax Paid Supplemental Data - - - $0
Short Term Debt Issuance - - - $14,609,915
Change In Other Current Assets - - - $-48,954
Fetched: 2026-06-17